Podium to Practice: Chicago 2025 – Melanoma: ECOG-ACRIN

Podium to Practice: Chicago 2025 – Melanoma: ECOG-ACRIN

Podium to Practice: Chicago 2025
Explore more from your favourite experts – click their name to access their entire library of content.
Icon Chair Speaker

Chair

Dr. Vanessa Bernstein

Icon Chair Speaker

Speakers

Dr. Omid Hamid

Dr. Elaine McWhirter

Studies / Trials Discussed

LBA9505 – A phase II randomized study of neoadjuvant pembrolizumab (P) alone or in combination with vidutolimod (V) in high-risk resectable melanoma: ECOG-ACRIN EA6194.

Studies/trials discussed:

LBA9505 – A phase II randomized study of neoadjuvant pembrolizumab (P) alone or in combination with vidutolimod (V) in high-risk resectable melanoma: ECOG-ACRIN EA6194.
Tagged